|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
SINIL PHARMACEUTICAL CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name SINIL PHARMACEUTICAL CO.,LTD. Headquarters SAN 5-1, BONPYEONG-RI, ANGSEONG-MYEON, CHUNGJU-SI, CHUNGCHEONGBUK-DO; Chungju; Chungcheongbuk; 380862 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: SANGROK (2011) Incorporation Date: December 21, 1977 Total Employees: 291 Tel: 043-722-3300 |
|
Company Description |
| Sales increased on strong sales networks and strong demand for its key products. Its profit increased on reduced administrative costs, although its manufacturing cost increased. The company acquired a number of patents for some medicines. Sales are expected to increase on strong sales of its key and new products. Its profitability is forecast to improve on reduced administrative costs and manufacturing costs. Its financial status is expected to improve on good cash flows and ample liquidity. |
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues increased with 23.32%, from KRW 16,110,480 thousands to KRW 19,866,672 thousands. Operating result increased from KRW 1,259,529 thousands to KRW 2,823,980 thousands which means 124.21% change. The results of the period increased 90.95% reaching KRW 2,549,143 thousands at the end of the period against KRW 1,335,000 thousands last year. Return on equity (Net income/Total equity) went from 2.64% to 4.73%, the Return On Asset (Net income / Total Asset) went from 2.26% to 4.09% and the Net Profit Margin (Net Income/Net Sales) went from 8.29% to 12.83% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 15.79% compared to 16.80% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 7.13 to 5.55 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
62,348,928 |
60,702,645 |
| ||
Current Assets |
36,640,039 |
34,840,699 |
| ||
Total Liabilities |
8,503,555 |
8,798,819 |
| ||
Shareholders Equity |
53,845,373 |
51,903,826 |
| ||
Current Liabilities |
6,596,357 |
5,937,537 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
19,866,672 |
33,729,178 |
| ||
Operational Profit (Loss) |
2,823,980 |
3,313,931 |
| ||
Net Profit (Loss) |
2,549,143 |
3,111,516 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
4.09% |
5.13% |
| ||
Return on Equity (ROE) |
4.73% |
5.99% |
| ||
Return on Sales (ROS) |
12.83% |
9.22% |
| ||
Return on Capital |
4.57% |
5.68% |
| ||
Gross Profit Margin |
46.67% |
48.9% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.54x |
0.97x |
| ||
Asset Turnover |
0.32x |
0.56x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
1,796,379 |
2,097,345 |
| ||
EBITDA |
2,840,734 |
3,350,501 |
| ||
Bookvalue (BV) |
49,665,475 |
47,993,203 |
| Liquidity Ratios | ||
| ||
Current Ratio |
555.46% |
586.79% |
| ||
Quick ratio |
450.76% |
471.91% |
| ||
Doom's day ratio |
59.54% |
41% |
| ||
Cash Flow to Debt |
17.78% |
-28.73% |
| Leverage Ratios | ||
| ||
Leverage ratio |
115.79% |
116.95% |
| ||
Interest Coverage Ratio |
2,276.06% |
1,156.07% |
| ||
Debt to equity |
15.79% |
16.95% |
| ||
Debt to total assets |
13.64% |
14.49% |
| ||
Long Term Debt to Capital |
3.42% |
5.22% |
| Market ratios | ||
| ||
Price/Book Ratio |
0.43 |
0.40 |
| Trend Ratios | ||
| ||
Revenue Trend |
123.32% |
93.27% |
| ||
Net Income Trend |
190.95% |
78.78% |
| ||
 |